United Therapeutics (UTHR) Income from Discontinued Operations (2010 - 2011)
United Therapeutics (UTHR) posted Income from Discontinued Operations of 69000.0 for Q3 2011, down 246.81% sequentially from 47000.0 in Q2 2011, and up 82.31% YoY from 37848.1 in Q3 2010.
United Therapeutics (UTHR) Income from Discontinued Operations (2010 - 2011) Analysis & Trends
United Therapeutics has reported Income from Discontinued Operations for 2 years, with the latest figure at 69000.0 in Q3 2011.
- Quarterly Income from Discontinued Operations rose 82.31% year-over-year to 69000.0 in Q3 2011, while the trailing twelve-month figure through Dec 2011 was 7000.0 (changed N/A YoY) and the FY2011 annual result came in at 7000.0, up 100.13% from the prior year.
- Income from Discontinued Operations retreated to 69000.0 in Q3 2011 per UTHR's latest filing, from 47000.0 in the prior quarter.
- Over five years, Income from Discontinued Operations peaked at 47000.0 in Q2 2011 and troughed at 4634000.0 in Q4 2010.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | -69,000.00 |
| Jun 30, 2011 | 47,000.00 |
| Mar 31, 2011 | 29,000.00 |
| Dec 31, 2010 | -4.63 Mn |
| Sep 30, 2010 | -390,000.00 |
| Jun 30, 2010 | -259,000.00 |